IDH1 and cholangiocarcinoma: Although the resistance to anti-IDH1/2 drugs was observed in cholangiocarcinoma and could represent an obstacle to the long-term treatment of patients with IDH inhibitors, this problem may be overcome by the use of dual inhibitors (targeting both IDH1 and IDH2), which are currently under evaluation.